BioSpace News Archive

Drug Development

Sophiris Bio Reports Top-Line Interim Safety and Biopsy Findings For its Phase 2b Clinical Trial of Topsalysin in Localized Prostate Cancer

A single administration of topsalysin continues to demonstrate an ability to ablate targeted prostate cancer cells with 10 of 35 patients (29%) demonstrating a clinical response of which 6 patients had a complete ablation with no detectable cancer on targeted biopsy of the treated area.

June 25, 2018
·
12 min read
Biotech Bay

NDS Launches All-in-One Image Management Solution Designed to Simplify OR Integration

NDS is now shipping its new video image management and acquisition solution: VIMA

June 25, 2018
·
2 min read
Business

Building the West Coast team and welcoming Kirk Tousaw and Mat Beren to the Canopy Growth family

Canopy Growth Corporation is pleased to announce the addition of well-respected cannabis industry leaders Kirk Tousaw and Mat Beren to its West Coast bench.

June 25, 2018
·
5 min read
Deals

Palatin Technologies Added to Russell 3000® Index

Palatin Technologies, Inc. announced that it has been added to the Russell 3000® Index as part of the annual Russell U.S. Index reconstitution.

June 25, 2018
·
3 min read
Drug Development

Pfizer Announces Overall Survival Results from Phase 3 PALOMA-3 Trial of IBRANCE® (Palbociclib) in HR+, HER2- Metastatic Breast Cancer

Results show a positive trend in the secondary endpoint of overall survival, though not reaching statistical significance

June 25, 2018
·
11 min read
Business

Synthetic Genomics Appoints Reinhard J. Ambros, Ph.D., Former Global Head of the Novartis Venture Fund to Board of Directors

Dr. Ambros was the global head of the Novartis Venture Fund from 2005 to 2017 and built one of the largest and most active corporate Biotechnology Venture Funds globally.

June 25, 2018
·
3 min read
Drug Development

Pulmatrix Announces Positive Top-Line Results from Parts 1 and 2 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

All doses were well tolerated in normal healthy volunteers in Parts 1 and 2 at up to 35 mg of itraconazole, the maximal dose planned

June 25, 2018
·
6 min read
Drug Development

Xeris Pharmaceuticals Announces Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen

Results of two Phase 3 studies presented at the American Diabetes Association’s 78th Scientific Sessions

June 25, 2018
·
6 min read
Biotech Beach

DermTech Announces Clinical Study to Assess DNA Damage and Reversal

DermTech, Inc. announced it has initiated enrollment in a clinical study to assess DNA damage induced by an excimer laser and evaluate the potential of T4 endonuclease topical DNA repair enzyme and photolyase cream

June 25, 2018
·
1 min read
Drug Development

Genentech’s TECENTRIQ in Combination with Chemotherapy Helped People with Previously-Untreated Extensive-Stage Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy

IMpower133 is the first Phase III study with an immunotherapy-based combination to show improvement in overall survival and progression-free survival in the initial treatment of extensive-stage small cell lung cancer

June 25, 2018
·
10 min read